Preclinical Therapeutic Antibody and Albumin-Conjugate Evaluation Poster

The JAX Humanized FcRn platform offers a number of critical solutions including evaluating pharmacokinetics and the bioavailability of human therapeutic monoclonal antibodies and human antibody-albumin conjugates in vivo. Using unique genetically modified mice with human Fc receptors, developed by Prof. Derry Roopenian at JAX, our In Vivo Pharmacology Team has performed over 35 external, multiphase studies to characterize human antibody half-life and develop dosing schedules needed for in vivo preclinical efficacy studies.